

AUGUST 2021 REPORT

CANNABIS USE FOR CONDITIONS ASSOCIATED WITH HIV AND AIDS

THE QUESTION

Patients with HIV and AIDS have long advocated for medical cannabis legislation, and they were among the first legal patients.

For what conditions and symptoms associated with HIV and AIDS do patients use cannabis for? What strains do they prefer?

FOR MORE INFORMATION CONTACT



205 East 42nd Street 14th floor New York, NY 10017



+1 917.210.0543



info@ryah.com



https://ryah.com https://ryahgroup.com/

THE ANSWER

Between January 1, 2018, and August 26, 2021, patients logged sessions within the RYAH Data ecosystem for fatigue, nausea, cachexia, wasting syndrome, inflammation, and many other complications from HIV/AIDS.

Mental health (depression, anxiety), pain, fatigue, and inflammation ranked among the top conditions treated.

As in the case in other demographic segments, men report using cannabis slightly more than women.

Patients preferred specific strains to treat each condition, with CBD-rich strains for mental health and THC-rich strains for pain.



RATES OF CANNABIS CONSUMPTION RANGE FROM 40% TO 74% AMONG PEOPLE LIVING WITH HIV [1]

ANALYSIS

RYAH Data is capable of tracking many complications and symptoms related to HIV/AIDs but not the infection itself.


Can cannabis treat HIV/AIDS as well as the symptoms? Several recent studies over the last decade have found that chronic cannabis use among people living with HIV/AIDS reduces plasma HIV-1 RNA viral loads.

One study explored viral loads among patients who also used injection drugs, while the other cocaine. [2][3]


More research is needed among broader populations to understand cannabis use on viral load supression.

CONDITIONS


TOTAL SESSIONS LOGGED



BY GENDER



MENTAL HEALTH



PAIN


HEPATITIS C Female Female 44.5% 45.9% Male Male 54.1% 55.5%

INFLAMMATION

Male

55.1%

NAUSEA



ANALYSIS


In 2005, the Journal of Pain Symptom Management published "Cannabis use in HIV for pain and other medical symptoms." [4]

Using a questionnaire model, the authors concluded, "Symptom control using cannabis is widespread in HIV outpatients." Up to 27% of respondents reported using cannabis to manage symptoms.

Of those, the most common reasons were as follows:

- Appetite (97%)
- Muscle Pain (94%)
- Nausea (93%)
- Anxiety (93%)
- Nerve Pain (90%)
- Depression (86%)

FAVORITE STRAINS



ADDITIONAL SOURCES

[1] Cecilia T. Costiniuk, Zahra Saneei, Syim Salahuddin, Joseph Cox, Jean-Pierre Routy, Sergio Rueda, Sara J. Abdallah, Dennis Jensen, Bertrand Lebouché, Marie-Josée Brouillette, Marina Klein, Jason Szabo, Charles Frenette, Andreas Giannakis, and Mohammad-Ali Jenabian.Cannabis and Cannabinoid Research.Sep 2019.204-213.http://doi.org/10.1089/can.2018.006

[2] Milloy, M-J et al. "High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs." Drug and alcohol review vol. 34,2 (2015): 135-40. doi:10.1111/dar.12223

[3] Slawek, Deepika E et al. "Daily and near-daily cannabis use is associated with HIV viral load suppression in people living with HIV who use cocaine." AIDS care, 1-8. 4 Aug. 2020, doi:10.1080/09540121.2020.1799922

[4] Woolridge, Emily et al. "Cannabis use in HIV for pain and other medical symptoms." Journal of pain and symptom management vol. 29,4 (2005): 358-67. doi:10.1016/j.jpainsymman.2004.07.011

FOR MORE INFORMATION CONTACT



205 East 42nd Street 14th floor New York NY 10017



+1 917.210.0543



info@ryah.com



https://ryah.com

DISCLAIMER

This Report is intended to be used strictly for informational purposes only and is not intended to constitute, or be a substitute for, medical advice and should not be relied upon in any such regard. Readers are strongly urged to consult a qualified healthcare professional and conduct independent research in respect of any questions regarding the information set out in the Report. This Report does not reflect all available scientific research on the subject matter of this Report and is not intended as an exhaustive resource. It is also possible that other relevant scientific findings (including conflicting findings) may have been reported since the date of this Report or of the information referred to herein. Accordingly, RYAH Medtech Inc. and it's associated and affiliated companies (collectively, the "RYAH Group") assume no responsibility for omissions or incomplete information in this Report.

The inclusion of any third party reference in this Report is not intended to be, and should not be construed as, an endorsement of such third party resource or of the treatments, programs or other information discussed therein. Although reasonable care has been taken in the preparation of the information contained in this Report, such information is provided on an "as-is" basis. None of the members of the RYAH Group make, in any manner, any representation, warranty, guarantee, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

The RYAH Group shall not be responsible for, and shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Report or the use (or misuse) thereof, under any theory of liability and even if advised of the possibility thereof. Anyone using the information in the Report does so at their own risk, and by using such information, agrees to indemnify each member of the RYAH Group and its content providers and directors and officers from any and all liability, loss, damages, costs, and expenses (including legal fees and expenses) arising from such person's use of the information in the Report.